Becton Dickinson and Co (BDX) : Bristol John W Co Inc Ny reduced its stake in Becton Dickinson and Co by 3.38% during the most recent quarter end. The investment management company now holds a total of 401,661 shares of Becton Dickinson and Co which is valued at $71,973,635 after selling 14,037 shares in Becton Dickinson and Co , the firm said in a disclosure report filed with the SEC on Oct 11, 2016.Becton Dickinson and Co makes up approximately 1.97% of Bristol John W Co Inc Ny’s portfolio.
Other Hedge Funds, Including , Carroll Financial Associates boosted its stake in BDX in the latest quarter, The investment management firm added 191 additional shares and now holds a total of 4,579 shares of Becton Dickinson and Co which is valued at $820,511. Becton Dickinson and Co makes up approx 0.12% of Carroll Financial Associates’s portfolio.Central Bank Trust Co reduced its stake in BDX by selling 350 shares or 3.87% in the most recent quarter. The Hedge Fund company now holds 8,699 shares of BDX which is valued at $1,543,203. Becton Dickinson and Co makes up approx 0.44% of Central Bank Trust Co’s portfolio. Hefty Wealth Partners added BDX to its portfolio by purchasing 388 company shares during the most recent quarter which is valued at $68,540. Becton Dickinson and Co makes up approx 0.05% of Hefty Wealth Partners’s portfolio.Bnp Paribas Arbitrage Sa reduced its stake in BDX by selling 27,316 shares or 20.6% in the most recent quarter. The Hedge Fund company now holds 105,296 shares of BDX which is valued at $18,600,538. Becton Dickinson and Co makes up approx 0.08% of Bnp Paribas Arbitrage Sa’s portfolio.West Oak Capital boosted its stake in BDX in the latest quarter, The investment management firm added 2,875 additional shares and now holds a total of 2,921 shares of Becton Dickinson and Co which is valued at $515,995. Becton Dickinson and Co makes up approx 0.36% of West Oak Capital’s portfolio.
Becton Dickinson and Co closed down -5.22 points or -2.91% at $173.97 with 9,85,936 shares getting traded on Tuesday. Post opening the session at $178.7, the shares hit an intraday low of $173.27 and an intraday high of $178.7 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Becton Dickinson and Co reported $2.35 EPS for the quarter, beating the analyst consensus estimate by $ 0.15 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $2.20. The company had revenue of $3198.00 million for the quarter, compared to analysts expectations of $3202.11 million. The company’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 EPS.
Many Wall Street Analysts have commented on Becton Dickinson and Co. Becton Dickinson and Co was Downgraded by Citigroup to ” Sell” on Sep 23, 2016.
Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.